Oxurion
oxurion.com
Actively hiring
Health Care
Research Institutes
Clinical Trial Services (CRO)
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
501-1000
employees, estimated range
Grants
$38k
1 grant · CORDIS
Backers
1
Pontifax
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jan 2020 | $38k | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Pontifax Similar startupsby what they do, their industry and backers
Lindus Health is an artificial intelligence native contract research organisation that runs clinical trials end to end. Founded in 2021 in…
The Innovation CRO. Curavit partners with a variety of sponsors to design and execute innovative clinical trials, leveraging our Virtual…
VivoSense is the wearable sensor CRO for clinical trials, delivering digital endpoint infrastructure, scientific expertise, and end-to-end…
Astraea automates SAPs, SDTM/ADaM, TLFs, Define-XML, QC, and FDA submission documents inside your environment. Sponsor-run software, not a…
A European group of independent freight forwarders, operating autonomously at local level while sharing scale, technology, and partnerships.
Paceline Bio runs the clinical ops layer behind biotech and pharma who want to move fast, from research to Phase 2: biospecimen collection…
News
OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC, The Goldman Sachs Group, Inc and Goldman Sachs International
Leuven, BELGIUM - September 30, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it
Read more
Report
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC, The Goldman Sachs Group, Inc and Goldman Sachs International
Read more
Report
Oxurion enters into exclusive negotiations to acquire the business and assets of Eclevar, a MedTech-focused CRO
Read more
Report
Oxurion Announces Results of the Extraordinary Shareholders' Meeting of 22 May 2023
Regulated Information Leuven, Belgium, Boston, MA, US - June 5, 2023 - 07.00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascula
Read more
Report
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Oxurion Provides Update On Recruitment For KALAHARI Phase 2, Part B Trial Of Novel Pkal Inhibitor THR-149 In Diabetic Macular Edema And Announces Board Changes
Read more
Report
Oxurion reports stronger data for diabetic eye disease drug
Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with diabetic macular oedema (DME) who don't respond to standard therapy.
Read more
Report
Financials
Total raised
$38k
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2020 | $38k | Details |